SCM
KRTX

Silverarc Capital Management’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Silverarc Capital Management’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-10,323
Closed -$2.32M – 103
2022
Q3 		$2.32M Buy
+10,323
New +$2.09M 0.79% 41

Other funds holding KRTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Silverarc Capital Management's KRTX Position: Q4 2022 in Review

Silverarc Capital Management sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q4 2022, closing a stake of 10,323 shares — an estimated $2.32M sold.

Silverarc Capital Management first reported a position in KRTX in Q3 2022 and held it in 1 quarter. The position peaked at $2.32M in Q3 2022. 248 funds tracked by Wall St. Rank hold KRTX as of Q4 2022.

  • Silverarc Capital Management reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Silverarc Capital Management sold 10,323 Karuna Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $2.32M.
  • Silverarc Capital Management first reported a position in Karuna Therapeutics, Inc. Common Stock in Q3 2022 and held it in 1 quarter.
  • Silverarc Capital Management's Karuna Therapeutics, Inc. Common Stock position peaked at $2.32M in Q3 2022.
  • 248 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q4 2022.

Based on Silverarc Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.